Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
This article was originally published in Scrip
Executive Summary
Vivus has resubmitted its new drug application (NDA) with the US FDA for its experimental obesity treatment Qnexa (phentermine/topiramate), for a narrower patient population, which would include overweight men and women of non-childbearing potential.